This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Big Biotechs Hold Growth Potential in Second Half of 2019
by Ekta Bagri
We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
by Zacks Equity Research
Arbutus (ABUS) surges on clearance for a clinical study to evaluate its RNAi agent, AB-729 as a treatment for hepatitis B virus.
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
by Zacks Equity Research
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
Big Drugmakers That May Tread the M&A Path After Pfizer
by Kinjel Shah
There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
AstraZeneca Gives Detailed Data From Calquence Leukemia Study
by Zacks Equity Research
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
GILD vs. ILMN: Which Stock Is the Better Value Option?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?
Galapagos Ends Enrollment in Osteoarthritis Study Before Time
by Zacks Equity Research
Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.
CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
by Zacks Equity Research
CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
5 Biotech Stocks to Buy Right Now
by Zachary Stutler
here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.
Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO
by Zacks Equity Research
Gilead (GILD) presents data from a phase I study on experimental CAR T cell therapy, KTE-X19, at ASCO and announces collaboration with Humanigen.
Why Is Gilead (GILD) Down 3% Since Last Earnings Report?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $63.34, moving -0.05% from the previous trading session.
GILD or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GILD vs. ILMN: Which Stock Is the Better Value Option?
Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum
by Zacks Equity Research
Gilead (GILD) up 6.9% in the year so far on strong performance of HIV franchise and pipeline development efforts.
Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason
by Zacks Equity Research
Zacks.com featured highlights include: Gilead, Jazz, Amdocs, Arch Capital and Legg Mason
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GILD) Outperforming Other Medical Stocks This Year?
Agenus' (AGEN) Pipeline Progression on Track Amid Competition
by Zacks Equity Research
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary
by Zacks Equity Research
Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.
5 Best PEG Stocks Suitable for GARP Investors
by Urmimala Biswas
While P/E alone only gives an idea of stocks that are trading at a discount, PEG, while adding the growth element to it, helps to identify stocks that have solid potential.
Lilly's Crohn's Disease Candidate Meets Phase II Study Goals
by Zacks Equity Research
Lilly's (LLY) mirikizumab met primary endpoint and key secondary endpoints in phase II Crohn's disease study.
The Zacks Analyst Blog Highlights: Disney, Coca-Cola, Gilead, CME and Entergy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Disney, Coca-Cola, Gilead, CME and Entergy
Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?
by Zacks Equity Research
Alexion (ALXN) gains 30.7% on solid performance of lead drug Soliris and approval of Ultomiris.
Top Stock Reports for Disney, Coca-Cola & Gilead
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Coca-Cola (KO) and Gilead (GILD).